

# Bio-Hermes-001 Study

## Global Alzheimer's Platform Foundation

Bio-Hermes-001 set an unprecedented commitment to a **diverse participant pool**, ending enrollment with **24%** of participants representing traditionally underrepresented populations--22% of participants identified as Black or African American and Hispanic or Latino -- across three cohorts based on clinical screening procedures: cognitively normal (CN), mild cognitive impairment (MCI), and mild AD.

Due to a combination of the number of tests and the extensive representation of diverse participants, our robust database is anticipated to have additional statistical analysis from our partners showing AUC results from multi-variate (or pooled) biomarker relationships and, eventually, those with expertise in identifying predictive fast progressing individuals.

### About the Data and Samples

- Bio-Hermes-001 produced a singular inventory of more than 80,000 IRB-approved, clinically annotated and biomarker validated biospecimen collection across the disease continuum. Securely stored in a CLIA-approved lab with -80 degree freezers.
- The storage system is FDA 21CFR Part 11 compliant and staff GCP-compliant facilities.
- Bio-Hermes-001 specimen inventory consists of plasma samples, whole blood samples, and whole blood RNA samples. Participants in the study consented to these samples being sold and utilized for future research in Alzheimer's or related diseases.

**Sample sets are available under commercial terms.**

### About Bio-Hermes-001

Bio-Hermes-001 is a first-of-its-kind study comparing **15 digital tests** and **25 blood-based biomarkers** to evaluate their ability to identify amyloid plaques in the brain, traditionally done using an amyloid PET scan.

This study analyzed the relationship between these tests to reduce historical barriers to access to a timely Alzheimer's diagnosis and care while also building a robust genomic and proteomic data set from the vast diversity of participants enrolled in the study. The data is in an 18-month embargo period accessible only to Bio-Hermes partners and sites. *On June 30th, 2025, the data will be available upon request to all via the Alzheimer's Disease Data Initiative's AD Workbench.*

**For information about the data or samples**, including business terms and opportunities, please contact Lammert Albers, Chief Commercial Officer, [LAlbers@GlobalAlzPlatform.org](mailto:LAlbers@GlobalAlzPlatform.org).

### Bio-Hermes-001:

- 1000+ participants enrolled, 24% of whom are from traditionally underrepresented populations
- Digital Data collected includes Speech analytics, speech elicitation tasks, Cognitive assessment using adaptive psychophysics. Digital remote brain health screening measuring cognitive and motion functions
- Blood-Based Biomarkers include: pTau-231, Aβ40, Aβ42, Aβ42/42, pTau-181, pTau-217, APS, Proteomics, NfL, GFAP, APOE, Cytokines, Total Tau Brain Derived, BD Tau, Full Genome Sequence
- Other data collected includes Family history of the disease, Clinical trial history, Concomitant medications, Full demography collection with race & ethnicity as well as DOB, age, sex, marital status, years of education, occupation
- Traditional cognitive tests: MMSE, RVLA

Scan QR code to read more about the study.

